ALS drug shows modest hope in Late-Stage trial
NCT ID NCT01492686
First seen Jan 07, 2026 · Last updated Apr 29, 2026 · Updated 18 times
Summary
This study tested a drug called MCI-186 in 137 people with ALS, a nerve disease that weakens muscles over time. The goal was to see if daily infusions could slow the disease's progress over 24 weeks. While the drug was safe, it only showed a small effect on slowing decline, meaning it may help manage the disease but not stop or cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Study site
Osaka, Japan
Conditions
Explore the condition pages connected to this study.